All In Biotech

Drug Trial Radar · NCT02446132

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,197

Actual

Start

Nov 13, 2015

Primary completion

Sep 6, 2024

Study completion Sep 6, 2024

Sponsor

Sponsor type
Industry
First posted
May 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.

Conditions

  • Agitation in Patients With Dementia of the Alzheimer's Type

Interventions

  • AVP-786Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug (in current study) up to 3 months after last dose of study drug (up to Week 64)
  2. Number of Participants With Serious TEAETime frame: From first dose of study drug (in current study) up to 3 months after last dose of study drug (up to Week 64)
  3. Number of Participants With Potentially Clinically Significant Laboratory Test AbnormalitiesTime frame: Baseline (current study) up to 52 weeks
  4. Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) AbnormalitiesTime frame: Baseline (current study) up to 52 weeks
  5. Number of Participants With Any Abnormal, Clinically Significant Physical and Neurological Examination FindingTime frame: Baseline (current study), Week 52
  6. Number of Participants With Potentially Clinically Significant Abnormalities in Vital SignsTime frame: Baseline (current study) up to 52 weeks
  7. Change From Baseline in the Sheehan Suicidality Tracking Scale (S-STS) Total Score at Week 64Time frame: Baseline (current study), Week 64
  8. Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 52Time frame: Baseline (current study), Week 52
  9. Change From Baseline in the Epworth Sleepiness Scale (ESS) Score at Week 52Time frame: Baseline (current study), Week 52

Locations

227 sites in 10 countries. Site status is shown where the registry gives one.

  • MD First Research, LLC Site #767

    Chandler, Arizona

  • NoesisPharma, LLC

    Phoenix, Arizona

  • Perseverance Research Center, LLC

    Scottsdale, Arizona

  • Health Initiatives Research

    Fayetteville, Arkansas

  • Advanced Research Center, Inc. Site #835

    Anaheim, California

  • ATP Clinical Research, Inc. Site #763

    Costa Mesa, California

  • Behavioral Research Specialists, LLC

    Glendale, California

  • Irvine Center for Clinical Research

    Irvine, California

  • Sheenath Clinical Service Site #770

    Lakewood, California

  • Torrance Clinical Research Institute, Inc. Site #826

    Lomita, California

  • Collaborative Neuroscience Network, LLC.

    Long Beach, California

  • Alliance for Wellness, Inc dba Alliance for Research Site #789

    Long Beach, California

  • NRC Research Institute

    Orange, California

  • California Neurological Services

    Panorama City, California

  • Havana Research Institute Site 787

    Pasadena, California

  • Havana Research Institute

    Pasadena, California

  • Pacific Research Network, Inc. #1

    San Diego, California

  • Pacific Research Network, Inc. #2

    San Diego, California

  • HB Clinical Trials Inc.

    Santa Ana, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Viking Clinical Research

    Temecula, California

  • Lytle and Weiss, PLLC dba Clinical Trials of the Rockies

    Denver, Colorado

  • Coastal Connecticut Research, LLC

    New London, Connecticut

  • Research Center for Clinical Studies, Inc.

    Norwalk, Connecticut

  • Neurology of Central Florida Rsch Ctr Site #803

    Altamonte Springs, Florida

  • JEM Research Institute

    Atlantis, Florida

  • Negron Research Services / Humanity Clinical Research Site# 766

    Aventura, Florida

  • SFM Clinical Research, LLC Site #563

    Boca Raton, Florida

  • Bradenton Research Center Site #834

    Bradenton, Florida

  • Clinical Research Of Brandon, LLC Site #838

    Brandon, Florida

  • Clinical Research of Brandon

    Brandon, Florida

  • Meridien Research

    Brooksville, Florida

  • Quantum Laboratories, Inc.

    Deerfield Beach, Florida

  • Moonshine Research Center, Inc

    Doral, Florida

  • Science Connections, LLC Site #814

    Doral, Florida

  • Finlay Medical Research Corp

    Greenacres City, Florida

  • Direct Helpers Research Center #801

    Hialeah, Florida

  • Indago Research & Health Center, Inc.

    Hialeah, Florida

  • New Life Medical Research Center, Inc.

    Hialeah, Florida

  • Reliable Clinical Research,LLC

    Hialeah, Florida

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.